Overview

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Phase:
Phase 2
Details
Lead Sponsor:
Sarah Sammons, MD
Collaborator:
Daiichi Sankyo